Delays Experienced by Patients With Pediatric Cancer During the Health Facility Referral Process: A Study in Northern Tanzania.


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
11 2020
Historique:
entrez: 17 11 2020
pubmed: 18 11 2020
medline: 29 7 2021
Statut: ppublish

Résumé

It is estimated that 50%-80% of patients with pediatric cancer in sub-Saharan Africa present at an advanced stage. Delays can occur at any time during the care-seeking process from symptom onset to treatment initiation. Referral delay, the time from first presentation at a health facility to oncologist evaluation, is a key component of total delay that has not been evaluated in sub-Saharan Africa. Over a 3-month period, caregivers of children diagnosed with cancer at a regional cancer center (Bugando Medical Centre [BMC]) in Tanzania were consecutively surveyed to determine the number and type of health facilities visited before presentation, interventions received, and transportation used to reach each facility. Forty-nine caregivers were consented and included in the review. A total of 124 facilities were visited before BMC, with 31% of visits (n = 38) resulting in a referral. The median referral delay was 89 days (mean, 122 days), with a median of two facilities (mean, 2.5 facilities) visited before presentation to BMC. Visiting a traditional healer first significantly increased the time taken to reach BMC compared with starting at a health center/dispensary (103 The majority of patients were delayed during the referral process, but receipt of a referral to a higher-level facility significantly shortened delay time. Referral delay for pediatric patients with cancer could be decreased by raising awareness of cancer and strengthening the referral process from lower-level to higher-level facilities.

Identifiants

pubmed: 33201744
doi: 10.1200/GO.20.00407
pmc: PMC7713565
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1757-1765

Références

Lancet. 2010 Oct 2;376(9747):1186-93
pubmed: 20709386
Eur J Cancer. 2013 Jul;49(11):2555-64
pubmed: 23597721
Curr Opin Pediatr. 2013 Feb;25(1):3-15
pubmed: 23295716
Pediatr Blood Cancer. 2011 Jan;56(1):70-6
pubmed: 21058286
PLoS One. 2015 Sep 30;10(9):e0135230
pubmed: 26422208
Pediatr Blood Cancer. 2008 Oct;51(4):468-74
pubmed: 18454472
World J Surg Oncol. 2015 Feb 22;13:71
pubmed: 25889238
Pediatr Blood Cancer. 2011 Mar;56(3):341-8
pubmed: 21225909
Oncologist. 2015 Jul;20(7):780-8
pubmed: 26032138
Semin Pediatr Surg. 2012 May;21(2):136-41
pubmed: 22475119
J Glob Oncol. 2015 Sep 23;1(1):30-36
pubmed: 28804769
Lancet Oncol. 2019 Apr;20(4):483-493
pubmed: 30824204
World J Surg Oncol. 2012 Nov 27;10:257
pubmed: 23181624
Cancer. 1977 May;39(5):1923-9
pubmed: 66974
J Clin Oncol. 2010 May 20;28(15):2625-34
pubmed: 20404250
World J Surg Oncol. 2013 Apr 18;11:88
pubmed: 23597032
Ecancermedicalscience. 2017 Jul 28;11:755
pubmed: 28900468
Trans R Soc Trop Med Hyg. 2011 Dec;105(12):717-26
pubmed: 22047912
Lancet Oncol. 2013 Mar;14(3):e104-16
pubmed: 23434340
BMC Res Notes. 2015 Dec 12;8:772
pubmed: 26654449
Pediatr Blood Cancer. 2008 Nov;51(5):626-8
pubmed: 18668514
Surgery. 2016 Dec;160(6):1636-1644
pubmed: 27743716
Front Oncol. 2018 May 29;8:187
pubmed: 29896450
Oncologist. 2018 Dec;23(12):1453-1460
pubmed: 30082488
PLoS One. 2019 Aug 1;14(8):e0220769
pubmed: 31369640
Cancer. 1980 Dec 15;46(12):2717-22
pubmed: 6160902
AIDS. 1997;11 Suppl A:S217-25
pubmed: 9451988
Cancer. 1982 May 1;49(9):1945-51
pubmed: 6280851
Eur J Cancer. 2008 Nov;44(16):2388-96
pubmed: 18799306
Int J Cancer. 2015 Jun 15;136(12):2875-9
pubmed: 25408458
Int J STD AIDS. 2006 Jun;17(6):360-3
pubmed: 16734953
S Afr Med J. 1969 Aug 16;43(33):1028-31
pubmed: 5822931
Br Med J. 1968 Aug 24;3(5616):468-9
pubmed: 5666805
Lancet Oncol. 2008 Aug;9(8):721-9
pubmed: 18672210
J Glob Oncol. 2018 Sep;4:1-10
pubmed: 30241177
East Afr Med J. 2009 Jul;86(7):348-53
pubmed: 20499785
Lancet Oncol. 2015 Aug;16(8):e385-93
pubmed: 26248846

Auteurs

Luke Maillie (L)

Icahn School of Medicine at Mount Sinai, New York, NY.

Nestory Masalu (N)

Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania.

Judy Mafwimbo (J)

Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania.

Mastidia Maxmilian (M)

Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania.

Kristin Schroeder (K)

Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania.
Division of Pediatric Hematology/Oncology and Duke Global Cancer Program, Duke University Medical Center, Durham, NC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH